The global CAR T-cell therapy market is projected to expand significantly, growing from USD 3.87 billion in 2022 to an estimated USD 88.52 billion by 2032, reflecting a robust compound annual growth rate (CAGR) of 29.8% from 2023 to 2032. This growth is driven by ongoing clinical trials and the increasing incidence of cancer, highlighting the rising demand for advanced cancer treatments.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5028
The United States and China have led the way in CAR T-cell therapy trials, with Europe trailing behind in the number of clinical studies listed on ClinicalTrials.gov.
CAR T-cell therapies hold immense promise in revolutionizing cancer treatment by harnessing the body’s immune system to fight cancer. These therapies involve genetically modifying a patient’s T cells to express a chimeric antigen receptor (CAR) that specifically targets cancer cells, offering a personalized treatment approach.
Often referred to as a “miracle anticancer drug” due to their high success rates, CAR T-cell therapies involve a complex manufacturing process. This process includes collecting the patient’s T cells at a medical facility, then culturing them in specialized labs to create a treatment tailored to the individual. The key advantages of CAR T-cell therapy over traditional treatments are its ability to use the body’s own immune system to attack cancer cells, faster recovery times, and shorter treatment durations. Additionally, CAR T-cell therapies have the unique ability to remain active in the body, recognizing and targeting cancer cells even if the cancer returns.
Currently, CAR T-cell therapy is mainly used to treat cancers such as lymphoma, acute lymphocytic leukemia, and multiple myeloma. With its many benefits over conventional medications, CAR T-cell therapy has seen widespread adoption, driving significant growth in the market.
CAR T-Cell Therapy Market Companies
1. Johnson & Johnson Services, Inc.
Johnson & Johnson, a global leader in healthcare, has a strong presence in the CAR T-cell therapy market. The company’s expertise in immunotherapy is demonstrated by its innovative pipeline, including the development of CAR T-cell therapies for various cancers. Johnson & Johnson has worked on several partnerships to advance the potential of cell therapies, including collaboration with other pharmaceutical giants to bring breakthrough treatments to market.
2. Allogene Therapeutics
Allogene Therapeutics focuses on developing allogeneic (off-the-shelf) CAR T-cell therapies, which are designed to be more readily available and less costly than autologous CAR T therapies, where a patient’s own cells are used. Allogene’s pioneering work in the field aims to overcome some of the challenges related to the manufacturing complexities and costs associated with traditional CAR T therapies.
3. Lonza
Lonza is a global leader in the development and manufacturing of biologics, including CAR T-cell therapies. The company provides cell therapy manufacturing services to several pharmaceutical companies, assisting in the large-scale production of CAR T-cell therapies. Lonza’s expertise in gene and cell therapy manufacturing has made it an integral player in the CAR T market, ensuring the quality and scalability of these therapies.
4. Aurora Biopharma
Aurora Biopharma specializes in developing next-generation CAR T-cell therapies. Its focus is on improving the efficacy and safety of cell-based therapies for cancer treatment. Aurora Biopharma is dedicated to advancing its proprietary therapies for hematologic and solid tumor cancers, and it is working on enhancing the manufacturing process to make these therapies more accessible to patients.
5. Cartesian Therapeutics, Inc.
Cartesian Therapeutics is an innovative biotech company focused on the development of engineered T-cell therapies, including CAR T-cells, for the treatment of cancer and autoimmune diseases. The company is committed to advancing its proprietary platform to create highly effective and durable treatments, with a focus on leveraging mRNA technology to enhance the CAR T-cell production process.
6. Novartis
Novartis is one of the pioneers in the CAR T-cell therapy market, having launched Kymriah, the first FDA-approved CAR T-cell therapy for certain types of leukemia and lymphoma. Novartis continues to lead in CAR T-cell research and development, focusing on expanding the range of cancers that CAR T therapy can treat. Their ongoing trials and collaborations aim to improve the accessibility and outcomes of CAR T therapy.
7. Bristol-Myers Squibb
Bristol-Myers Squibb (BMS) has made significant contributions to the CAR T-cell therapy field, particularly through its acquisition of Celgene, which brought the CAR T-cell therapy Breyanzi (lisocabtagene maraleucel) to its portfolio. BMS continues to invest heavily in CAR T research, with several trials exploring new indications and improving treatment efficacy.
8. Gilead Sciences
Gilead Sciences is a leader in cell therapy through its acquisition of Kite Pharma, which developed Yescarta, one of the most widely used CAR T-cell therapies for treating certain lymphomas. Gilead is focused on expanding the indications for CAR T therapies, including exploring treatments for solid tumors. The company is also working to refine the manufacturing process to improve the cost-effectiveness and accessibility of CAR T therapies.
9. Curocell Inc.
Curocell Inc. is an emerging player in the CAR T-cell therapy market, focusing on the development of its proprietary therapies for cancer treatment. The company is advancing new CAR T-cell products that target a variety of cancers, including both hematologic malignancies and solid tumors. Curocell is dedicated to refining its CAR T therapies and improving patient outcomes through innovative treatments.
10. JW Therapeutics
JW Therapeutics is a leading Chinese biotechnology company that specializes in developing CAR T-cell therapies for cancer. The company is focused on improving the safety and efficacy of CAR T therapies while expanding their accessibility. JW Therapeutics is advancing its pipeline of CAR T therapies for the treatment of blood cancers, with a focus on lymphoma and leukemia.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/car-t-cell-therapies-are-poised-for-the-next-wave-of-innovation
Access exclusive insight now @ https://www.towardshealthcare.com/price/5028
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
